No difference in C3 and C4 resulted between ACPA positive and ACPA negative patients during the follow up. ESR, CRP and DAS28 levels were significanlty reduced at T1, T3, T6, T9, and T12 with the respect to T0 ( Figure 1A -C). C3 levels were significantly reduced at T3, T6, and T9 with the respect to T0 while C4 levels were significantly reduced at T3, T6, T9, and T12 with the respect to T0 ( Figure 1D -E). Positive correlations resulted between DAS28 and both C3 and C4 at T1 and T3 ( Figure 1F -I). C3 and C4 were directly related with ESR at T1 (C3: P 0.002; C4: P 0.005), T3 (C3: P 0.04; C4: P 0.03), and T6 (C3: P<0.0001; C4: P 0.002) and with CRP at T1 (C3: P 0.03; C4: P 0.01) and T6 (C3: P<0.0001; C4: P 0.03). When stratifying patients in accordance with the EULAR response to therapy, C3 decreased significantly in responders than in no-responders at T1; moreover, responders showed lower levels of both C3 and C4 at T1 and T3 with the respect to T0 ( Figure 1L -O).
Conclusions:
In RA patients, treatment with TCZ is able to reduce C3 and C4 levels in an early and substained way. Background: Biologic agents provide clinical benefits in patients with Rheumatoid Arthritis (RA) but they are associated with an increased risk of tuberculosis (TB) infection. Objectives: We investigated the accordance between the tuberculin skin test (TST) and the interferon-gamma (IFN-γ) release assay (IGRA) for the diagnosis of latent tuberculosis infection (LTBI) in patients with RA. The objective of our study was a direct comparison between the IGRA and the TST regarding LTBI diagnosis in RA patients before starting anti-TNF agents and at least one year after the initiation of treatment. Methods: RA consecutive patients have been included in the study both before and after 1 year of the initiation of TNF-α antagonist therapy. A standard questionnaire was completed for each patient, including basic demographic data and concurrent immunosuppressive therapy (corticosteroids, disease-modifying anti-rheumatic drugs [DMARDs], synthetic and biologics). The patients were screened for LTBI using IGRA and TST methods. All analyses were performed with IBM-SPSS Statistics for Windows (version 21). The kappa coefficient (κ) was calculated to determine the concordance between the two tests: TST and IGRA. The strength of the agreement was considered "poor" for κ ≤0.20, "low-moderate" for 0.20 < κ ≤0.40, moderate for 0.40 < κ ≤0.60, "substantial" for 0.60 < κ ≤0.80, and "optimal" for 0.80 < κ ≤1. Results: 78 patients (67 female, 11 male) have been screened with TST and IGRA. The accordance between TST and IGRA was 89.7% (κ 0.514, κ<0.001). A κ value of 0.514 represents a moderate accordance between the two tests. 6 female patients converted TST (4 became positive, and 2 became negative). No patient developed active tuberculosis. Conclusions: A moderate accordance between the two methods (TST and IGRA) was obtained. In the absence of a diagnostic gold standard for LTBI, different issues should be taken into consideration regarding the two methods (cost, laboratory expertise and equipment etc). More studies are needed in the field in order to elucidate the cost-effectiveness but also the appropriateness of both methods. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.6400
